Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes

Area of Science:

• Immunology
• Gene Therapy
• Molecular Biology

Background:

• Human T lymphocytes are crucial for immune responses.
• Efficient gene transfer into T cells is essential for developing novel therapies.
• Recombinant adenoviruses (rAd) are explored as vectors for gene delivery.

Purpose of the Study:

• To evaluate recombinant adenovirus MFG-AP (rAd-MFG-AP) for gene transfer into human T lymphocytes.
• To assess the efficiency of T lymphocyte transduction using cytokines and LipofectAMINE.
• To determine if transgene expression affects T lymphocyte function and phenotype.

Main Methods:

• CD3+ T cells were isolated and cultured with cytokines (IL-2, IL-7, IL-12).
• Transduction was performed using rAd-MFG-AP alone or complexed with LipofectAMINE.
• Reporter gene expression (alkaline phosphatase) was quantified by flow cytometry.
• Immunophenotyping and cytotoxicity assays were used to evaluate T cell function.

Main Results:

• IL-2 combined with IL-7 or IL-12 enhanced rAd-MFG-AP transduction efficiency to 11-12%.
• LipofectAMINE significantly increased transduction efficiency to 22-24% when combined with cytokines.
• Transduced T lymphocytes maintained their surface antigens and cytotoxic function.
• No specific T lymphocyte subtype showed increased susceptibility to transduction.

Conclusions:

• Adenovirus-LipofectAMINE complexes enable efficient gene transfer into human T lymphocytes under clinical conditions.
• Cytokine pre-treatment (IL-2 with IL-7 or IL-12) is beneficial for T lymphocyte transduction.
• This approach preserves T lymphocyte function and phenotype, suggesting therapeutic potential.